Promising drug for hand and foot blisters falls short in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Adults aged 18 years of age and older * Dermatologist confirmed diagnosis of PPP for at least 6 months * Moderate-severe PPP, defined as a ppPASI \> 12 * Inadequate response to topical therapy and a candidate for systemic or phototherapy * Willing to discontinue current topical and/or systemic PPP treatments, except for OTC emollients Exclusion Criteria: * • Participants with other immune-mediated conditions requiring concurrent systemic immunosuppressant treatments * Current/recent administration of PPP-specific medications including: * Rituximab within 6 months of the baseline visit * Biologics within 12 weeks of baseline visit * Systemic steroids, oral immunosuppressants (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, tacrolimus), oral retinoids (acitretin, isotretinoin), apremilast, or dapsone within 4 weeks of baseline visit * Phototherapy within 4 weeks of baseline visit * Prescription topical medications (including calcineurin inhibitors, crisaborole, retinoids, steroids, tar, vitamin D analogs) within 2 weeks of baseline visit * History of active infection and/or febrile illness within 7 days; or infection requiring antibiotic treatment within 30 days; or serious infection requiring hospitalization and/or IV antibiotics within 90 days * Evidence of other infection including: * Active or untreated latent tuberculosis, defined as radiographic or laboratory evidence of active TB or positive quantiferon or PPD, unless the subject has completed the recommended treatment * Human immunodeficiency virus infection (positive HIV antibody) * Active hepatitis B * Active hepatitis C * Evidence of clinically significant laboratory abnormality including: * Absolute WBC count \< 3000/mm3 * Platelet count \< 100,000/mm3 * Hemoglobin \< 9.0 g/dl * ALT or AST \> 3 times the upper limit of normal * History of cancer within the past 5 years, excluding treated non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) * Other uncontrolled chronic medical condition that may interfere with a patient's ability to participate in the clinical trial * Major surgery within 4 weeks of baseline visit * Receipt of live vaccine within 8 weeks of baseline visit * Pregnant or breastfeeding individuals * Inability to comply with any of the study procedures * Individuals who are incarcerated or compulsory detained